Velpatasvir-d3

Velpatasvir-d3 (GS-5816-d3) is deuterium labeled Velpatasvir. Velpatasvir (VEL, GS-5816) is a novel pan-genotypic hepatitis C virus (HCV) nonstructural protein 5A (NS5A) inhibitor with activity against genotype 1 (GT1) to GT6 HCV replicons. Velpatasvir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 2.16 μM[1][2][3].

Product Specifications

Product Name Alternative

GS-5816-d3

UNSPSC

12352005

Target

HCV; Isotope-Labeled Compounds; SARS-CoV

Type

Isotope-Labeled Compounds

Related Pathways

Anti-infection; Others

Field of Research

Cancer; Infection; Inflammation/Immunology

Smiles

O=C(OC)N[C@@H](C(C)C)C(N1[C@@H](C2=NC3=CC=C4C=C5C(OCC6=C5C=CC(C7=CNC([C@H]8N(C([C@H](NC(OC([2H])([2H])[2H])=O)C9=CC=CC=C9)=O)C[C@@H](COC)C8)=N7)=C6)=CC4=C3N2)CC[C@@H]1C)=O

Molecular Formula

C49H51D3N8O8

Molecular Weight

886.02

References & Citations

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53 (2) :211-216.|[2]Yasmeen S, et al. An insight into the hepatoprotective role of Velpatasvir and Sofosbuvir per se and in combination against carbon tetrachloride-induced hepatic fibrosis in rats. Environ Sci Pollut Res Int. 2023 Sep;30 (42) :95660-95672.|[3]Lawitz EJ et al. Clinical Resistance to Velpatasvir (GS-5816), a Novel Pan-Genotypic Inhibitor of the Hepatitis C Virus NS5A Protein. Antimicrob Agents Chemother. 2016 Aug 22;60 (9) :5368-78.|[4]Qi Sun, et al. Bardoxolone and bardoxolone methyl, two Nrf2 activators in clinical trials, inhibit SARS-CoV-2 replication and its 3C-like protease. Signal Transduct Target Ther. 2021 May 29;6 (1) :212.